As part of the global health community, biopharmaceutical companies are committed to playing the greatest possible role in the global response to COVID-19.

The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) is the global association of the world’s leading biopharmaceutical companies. Our members have a breadth of expertise (research, clinical development, manufacturing) that uniquely positions our industry to support the fight against the spread of COVID-19.

We have a strong sense of responsibility to act together, as well as in partnership with the World Health Organization (WHO), governments and health systems across the world in a concerted, collective response.

Already, our industry has responded on an unprecedented scale to the current pandemic

And here we commit to...

- rapidly screen the industry’s vast libraries of medicines to identify potential treatments and undertake numerous clinical trials to test new and existing therapies.
- share real-time clinical trial data with governments and other companies around the world to advance the development of additional therapies.
- use our expertise and know-how to speed up the development of safe and effective vaccines to prevent COVID-19 in partnership with others.
- use our medical expertise to support global healthcare systems to manage the unprecedented increase in pressure they are experiencing.
- share tools and insights to test potential therapies and vaccines as well as to develop and scale up the capacity of diagnostics testing for COVID-19 patients as much as possible.
- increase our manufacturing capabilities and share available capacity to ramp up production once a successful vaccine or treatment is developed.
- work to secure continuity of supply for all essential medicines, vaccines, and diagnostics for patients with other life-threatening diseases, urging governments to implement policies and decisions that facilitate access for all those in need.

19 March 2020 | Thomas Cueni, Director General, IFPMA